Alila Hotels Beckons Travelers to Experience the Luxury of Wonder Through Global Campaign, A World Awaits
8.9.2025 16:30:00 CEST | Business Wire | Press Release
Today, Hyatt Hotels Corporation (NYSE:H) announces Alila, part of Hyatt’s Luxury Portfolio of brands, is inviting travelers to discover a more connected world by unveiling a new creative campaign, A World Awaits. The campaign also introduces Alila Moments—enriching, immersive and personalized guest experiences that span culture and community, nature and environmental awareness, creativity, and wellness.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250908156308/en/
A World Awaits Campaign by Alila
A World Awaits explores how we travel to see the world and yet the most powerful journeys turn our gaze inward. This campaign invites guests to experience place with presence, to take in the vastness of a destination and feel its echo within. Through juxtaposing visuals of the vast and beautiful Alila destinations paired with imagery of deeply personal guest moments of immersion and mindfulness, A World Awaits emphasizes the emotional reasons behind our guests’ journeys to other parts of the world. This approach invites travelers to awaken their spirit of adventure—from the world around us to the world within us.
A World Awaits also marks the debut of the Alila Moments platform – a refined collection of immersive, signature brand experiences set to be live at all hotels across the brand’s global portfolio. Exclusive, one-of-a-kind, and thoughtfully crafted, the brand’s thoughtful intention with Alila Moments is to foster transformational connections between guests and the community, rooted in local wisdom, the distinct culture, and their fellow travelers – designed for an impact that lingers long after check-out.
Alila is a brand known for curating moments of discovery, serenity, and immersion, with wellness, care for the environment, and respect for local tradition at the core. With A World Awaits, Alila hotels underscore the brand’s purpose and introduces new Alila Moments for curious travelers to embrace uncharted landscapes, whether that be physical and natural terrain or mental and spiritual groundwork.
ALILA MOMENTS
Firmly grounded in the distinct facets of each Alila hotel’s destinationand available exclusively to Alila guests, each Alila Moments experienceis curated for those seeking different, deeper ways to explore a specific destination and its natural beauty.
From a spiritual cold plunge in a Big Sur River amongst Redwood trees, to a Shahpura crafts-making crawl with traditional Indian spa practice to end the day, Alila Moments offer space for guests to go beyond themselves to discover and genuinely connect with the surrounding environment through uniquely personalized and transformative experiences. Notable Alila Moments include:
- Alila Ventana Big Sur in California | Coldstream Bliss: A Big Sur Ritual: Visitors are invited to bathe in the beauty of Big Sur with a private, guided, half-mile hike through the iconic Redwoods, featuring a dynamic combination of breathwork, intention setting exercises, and a river cold plunge that will leave them feeling refreshed, energized and deeply alive.
- Alila Fort Bishangarh in India | Back to the Roots: A Tour of Rajasthan’s Artisanal Heritage: Guests will discover Rajasthan’s creative soul as they spend an intimate day with the region's best artisans on this journey through Shahpura. Participants will have the opportunity to create their own pottery, bangles and runs under a local expert’s guidance, and following, will experience a traditional Ayurvedic head, neck, and shoulder massage.
- Alila Villas Uluwatu in Bali | The Spiritual Essence of Bali: A Journey of Ritual, Reflection, and Wonder: Through this immersion into the spiritual rhythms of Bali, guests will experience a day that begins with sacred cleansing and continues with traditional crafts, temple offerings, local cuisine, and a mesmerizing Kecak performance at sunset.
- Alila Hinu Bay in Oman | Sacred Resin: A Ritual of Frankincense and Renewal: Guests will explore where ancient Omani traditions and the sacred essence of Frankincense converge, beginning with crafting a personalized frankincense scrub in the spa kitchen, followed by a restorative full-body ritual of exfoliation, massage, and head treatment. The Moment continues with a five-course frankincense-infused dinner and storytelling with a local Omani about the historical and spiritual symbolism of this substance.
- Alila Shanghai in Greater China | The Fragrant Path: Incense, Memory, and Meaning: Step into the poetic world of Chinese incense and its role in healing, meditation, and artistry. Guests will create their own blend and reflect on scent as a tool for presence, memory, and personal balance.
“A World Awaits is a pivotal campaign for the Alila brand, reinforcing its commitment to the luxury traveler who cherishes every step that they take, believes in moments of wonder large and small, and cares about the planet as much as they care about themselves,” said Katie Johnson, vice president, global brand leader, luxury portfolio, Hyatt. “From cultural and environmental immersion, to enriching bespoke experiences and holistic wellbeing, with this campaign, Alila hotels look forward to guests experiencing the worlds of culture, tradition, nature, spirituality and more, that await them at every corner.”
Set in 18 awe-inspiring destinations across Indonesia, Maldives, Oman, India, China, Malaysia, and California, the Alila brand brings to life A World Awaits across all of its global properties, including the newest addition, Alila Dong’ao Island Zhuhai, a luxury all-suite clifftop resort perched at the southwestern tip of Dong’ao Island in Zhuha. Looking ahead, Alila Mayakoba will join the brand in late 2025 as the first Alila property in Latin America.
To learn more about the Alila brand, please visit www.alilahotels.com.
About Alila
Alila is a global, luxury hotel brand inviting travelers to discover a more connected world through cultural and environmental immersion, enriching experiences, and holistic wellbeing. Alila hotels live in harmony with their natural surroundings—where simplicity reveals profound beauty, and embrace their local communities, allowing guests to re-discover the luxury of living. At the heart of the brand and furthering its commitment to cultural and environmental immersion is Alila Moments, a collection of one-of-a-kind, exclusive experiences that expose guests to a destination's unique facets and leave a lasting impact designed to remain long after they return home. In support of sustainable tourism, all Alila hotels that have been in operation for at least one year are EarthCheck certified, integrating the natural, physical and cultural elements of their environments. For more information, visit alilahotels.com, follow on Instagram @AlilaHotels, or like on Facebook.
About Hyatt Hotels Corporation
Hyatt Hotels Corporation, headquartered in Chicago, is a leading global hospitality company guided by its purpose – to care for people so they can be their best. As of June 30, 2025, the Company's portfolio included more than 1,450 hotels and all-inclusive properties in 80 countries across six continents. The Company's offering includes brands in the Luxury Portfolio, including Park Hyatt®, Alila®, Miraval®, Impression by Secrets, and The Unbound Collection by Hyatt®; the Lifestyle Portfolio, including Andaz®, Thompson Hotels®, The Standard®, Dream® Hotels, The StandardX, Breathless Resorts & Spas®, JdV by Hyatt®, Bunkhouse® Hotels, and Me and All Hotels; the Inclusive Collection, including Zoëtry® Wellness & Spa Resorts, Hyatt Ziva®, Hyatt Zilara®, Secrets® Resorts & Spas, Dreams® Resorts & Spas, Hyatt Vivid Hotels & Resorts, Sunscape® Resorts & Spas, Alua Hotels & Resorts®, and Bahia Principe Hotels & Resorts; the Classics Portfolio, including Grand Hyatt®, Hyatt Regency®, Destination by Hyatt®, Hyatt Centric®, Hyatt Vacation Club®, and Hyatt®; and the Essentials Portfolio, including Caption by Hyatt®, Unscripted by Hyatt, Hyatt Place®, Hyatt House®, Hyatt Studios, Hyatt Select, and UrCove. Subsidiaries of the Company operate the World of Hyatt® loyalty program, ALG Vacations®, Mr & Mrs Smith, Unlimited Vacation Club®, Amstar® DMC destination management services, and Trisept Solutions® technology services. For more information, please visit www.hyatt.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250908156308/en/
Contacts
MEDIA CONTACT:
Patrice Henry
Hyatt
Patrice.Henry@Hyatt.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom